Confluence Pharmaceuticals LLC, based in Indianapolis, IN, is dedicated to advancing research in Autism and Fragile X Syndrome, with the aim of developing innovative therapeutic treatments for core social and communication impairments. Their mission is to restore hope and unlock the potential of individuals affected by these disorders by improving important functionalities such as talking, thinking, social interaction, and self-care.
With a focus on changing the way people think about treating Fragile X and Autism, Confluence Pharmaceuticals is committed to bringing to market a solution that effectively addresses the core challenges faced by individuals with these conditions, ultimately enhancing their ability to communicate and socially interact in everyday life.
Generated from the website